Restoration of CD3 + CD56 + NKT‐like cell function by TIGIT blockade in inactive carrier and immune tolerant patients of chronic hepatitis B virus infection
European Journal of Immunology · 2024
DOI: 10.1002/eji.202451046 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Xiaojing Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Receptors, Immunologic, Hepatitis B, Chronic, CD56 Antigen, Hepatitis B virus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Scientific Research Foundation of Education Department of Anhui Province of China, Natural Science Foundation of Anhui Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chronic hepatitis B (CHB) virus infection, which can be divided into immune‐tolerant (IT), immune‐active (IA), inactive carrier (IC) phases, and HBeAg‐negative hepatitis (ENEG), can induce liver cirrhosis and eventually hepatocellular carcinoma (HCC). CD3 + CD56 + NKT‐like cells play an important role in antiviral immune response. However, the mechanism of NKT‐like cells to mediate immune tolerance remains largely elusive. In this study, we observed circulating NKT‐like cells from IC and IT CHB patients were phenotypically and functionally impaired, manifested by increased expression of inhibitory receptor TIGIT and decreased capacity of secreting antiviral cytokines. Besides, TIGIT + NKT‐like cells of IC and IT CHB patients expressed lower levels of cytotoxic cytokines than the TIGIT − subset. Furthermore, increased expression of CD155, the ligand of TIGIT, on plasmacytoid dendritic cells (pDCs) was detected in IC and IT CHB patients. Importantly, the co‐culture of NKT‐like cells and pDCs showed that NKT‐like cells restored their antiviral ability after TIGIT blockade upon HBV peptide stimulation in IC and IT CHB patients. In conclusion, our findings suggest that the TIGIT pathway may mediate immune tolerance in IT CHB patients and lead to functional impairment in IC patients, indicating that TIGIT may be a potential therapeutic checkpoint for immunotherapy of CHB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Inflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, China.
- Department of Basic and Clinical Pharmacy, School of Pharmacy, Anhui Medical University, Hefei, China.
- Department of Clinical Laboratory, Anhui Provincial Maternity and Child Health Hospital, Hefei, China.
ORCID-Profile: Lu Zong
Förderung
- Scientific Research Foundation of Education Department of Anhui Province of China
- Natural Science Foundation of Anhui Province
- National Natural Science Foundation of China
Zitieren
APA
Yu, X., Zheng, Y., Huang, R., Dai, X., Kang, G., Wang, X., Yan, G., Ding, B., Zheng, M., Xu, Y., & Zong, L. (2024). Restoration of CD3 + CD56 + NKT‐like cell function by TIGIT blockade in inactive carrier and immune tolerant patients of chronic hepatitis B virus infection. European Journal of Immunology. https://doi.org/10.1002/eji.202451046
Vancouver
Yu X, Zheng Y, Huang R, Dai X, Kang G, Wang X, et al. Restoration of CD3 + CD56 + NKT‐like cell function by TIGIT blockade in inactive carrier and immune tolerant patients of chronic hepatitis B virus infection. European Journal of Immunology. 2024. doi:10.1002/eji.202451046
BibTeX
@article{Yu2024,
author = {Yu, Xiaojing and Zheng, Yuanling and Huang, Ruoyu and Dai, Xiaoran and Kang, Guijie and Wang, Xuefu and Yan, Guoxiu and Ding, Biran and Zheng, Meijuan and Xu, Yuanhong and Zong, Lu},
title = {Restoration of CD3 + CD56 + NKT‐like cell function by TIGIT blockade in inactive carrier and immune tolerant patients of chronic hepatitis B virus infection},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202451046}
}
EUVIMED